Andrew John Phillips - 23 Feb 2023 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role
Director
Signature
/s/ Ben Hohl, by power of attorney
Issuer symbol
ELVN
Transactions as of
23 Feb 2023
Net transactions value
$0
Form type
4
Filing time
06 Apr 2023, 20:20:14 UTC
Previous filing
05 May 2022
Next filing
12 Jun 2023
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Andrew John Phillips filed Form 4 for Enliven Therapeutics, Inc. (ELVN) on 06 Apr 2023."

Quick Takeaways

  • This page summarizes Andrew John Phillips's Form 4 filing for Enliven Therapeutics, Inc. (ELVN).
  • 1 reported transaction and 1 derivative row are listed below.
  • Filing timestamp: 06 Apr 2023, 20:20.

What Changed

  • Previous filing in this sequence was filed on 05 May 2022.
  • Current net transaction value: $0.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELVN Stock Option (right to buy) Award $0 +27,567 $0.000000 27,567 23 Feb 2023 Common Stock 27,567 $25.28 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/36th of the shares subject to the option will vest on March 23, 2023 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Sponsored